The effect of carnitine supplementation for the liver cirrhosis patients with hyperammonemia -a preliminary randomized controlled study

The effect of carnitine supplementation for the liver cirrhosis patients with hyperammonemia -a preliminary randomized controlled study - Carnitine supplementation for the liver cirrhosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008723

Enrollment

Registered

2012-08-20

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis

Interventions

Study drug was 600mg t.d.s. carnitine per day for 8weeks. Study drug was 900mg t.d.s. carnitine per day for 8weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Liver cirrhosis patients who complicated hyperammonemia, despite of taking dietary management more than 30 days.

Exclusion criteria

Exclusion criteria: 1.Patients who are difficult to continue this study for treatment of hepatocarcinoma. 2.Patients complicated uncontrolled diabets. 3.Patients who diagnosed unfitness to attend the study by a physician.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is to evaluate the change of blood ammonia level.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026